Phenotypes associated with this allele

• Allele Symbol: Slc28a1^em1Govr
• Allele Name: endonuclease-mediated mutation 1, Rajgopal Govindarajan
• Allele ID: MGI:7643463
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Slc28a1^em1Govr/Slc28a1^em1Govr	C57BL/6NTac-Slc28a1^em1Govr	MGI:7645204

Genotype
MGI:7645204

hm1

• Allelic Composition: Slc28a1^em1Govr/Slc28a1^em1Govr
• Genetic Background: C57BL/6NTac-Slc28a1^em1Govr

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

mortality/aging ( J:336148 )

N • despite anemia no increase in mortality is seen at any age

hematopoietic system

anemia ( J:336148 )

• less severe than in Slc29a3 null mice

decreased erythrocyte cell number ( J:336148 )

• at 20 weeks of age

decreased hematocrit ( J:336148 )

• at 20 weeks of age

reticulocytosis ( J:336148 )

• compensatory increase in the number of reticulocytes and differential reticulocyte count at 20 weeks of age

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:336148 )

N • albuminuria is not observed and average urinary creatinine levels are similar to controls

increased circulating creatinine level ( J:336148 )

• increased serum creatinine at 20 weeks of age

increased circulating cholesterol level ( J:336148 )

increased circulating calcium level ( J:336148 )

decreased circulating chloride level ( J:336148 )

abnormal urine nucleoside level ( J:336148 )

• elevated levels of pyrimidine (deoxy)nucleosides (uridine, cytidine, deoxyuridine, deoxycytidine, and deoxythymidine) in the urine

• however, levels of purine (deoxy)nucleosides are not significantly different

abnormal metabolism ( J:336148 )

• significant changes to both the urine and plasma metabolomes related to changes in purine and pyrimidine metabolism

abnormal xenobiotic pharmacokinetics ( J:336148 )

• decreased plasma levels of nucleoside drugs due to increased urinary loss

• decreased therapeutic efficacy of anticancer drug gemcitabine that can be compensated by increasing the dose

renal/urinary system

abnormal urine nucleoside level ( J:336148 )

• elevated levels of pyrimidine (deoxy)nucleosides (uridine, cytidine, deoxyuridine, deoxycytidine, and deoxythymidine) in the urine

• however, levels of purine (deoxy)nucleosides are not significantly different